U.S., Aug. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07122076) titled 'GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases' on July 29.
Brief Summary: This study is a prospective single-arm open-label clinical trial, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in patients with moderate to severe refractory autoimmune diseases. A total of 10 subjects will be enrolled in this study.
Study Start Date: Aug. 20
Study Type: INTERVENTIONAL
Condition:
Autoimmune Diseases
Intervention:
BIOLOGICAL: GT719 Injection
GT719 Injection
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Grit Biotechnology
Published by HT Digital Content Services with ...